French pharmaceutical company Sanofi has said it will shed 466 jobs in France and Germany as part of the continuing restructure of its R&D group, and focus on immuno-oncology treatments, antibody engineering and gene therapies. In a statement, the company said the moves would allow it to "maximise the productivity of our research engine". The move comes after the European Commission approved an initial €1.3bn (£960m) package for restructuring the company, which is owned by GlaxoSmithKline (GSK).
French pharmaceutical company Sanofi has said it will shed 466 jobs in France and Germany as part of the continuing restructure of its R&D group, and focus on immuno-oncology treatments, antibody engineering and gene therapies. In a statement, the company said the moves would allow it to "maximise the productivity of our research engine". Sanofi has reduced its reliance on partners such as Alnylam and Regeneron in recent years and shuttered R&D projects outside oncology, immunology, rare diseases and vaccines.